Selected article for: "oral treatment and present study"

Author: Ansarin, Khalil; Tolouian, Ramin; Ardalan, Mohammadreza; Taghizadieh, Ali; Varshochi, Mojtaba; Teimouri, Soheil; Vaezi, Tahere; Valizadeh, Hamed; Saleh, Parviz; Safiri, Saeid; Chapman, Kenneth R.
Title: Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial
  • Cord-id: 7ba0huwy
  • Document date: 2020_7_19
  • ID: 7ba0huwy
    Snippet: [Image: see text] Introduction: Bromhexine is a potential therapeutic option in COVID-19, but no data from a randomized clinical trial has been available. The present study aimed to evaluate the efficacy of bromhexine in intensive care unit (ICU) admission, mechanical ventilation, and mortality in patients with COVID-19. Methods: An open-label randomized clinical trial study was performed in Tabriz, North-West of Iran. They were randomized to either the treatment with the bromhexine group or the
    Document: [Image: see text] Introduction: Bromhexine is a potential therapeutic option in COVID-19, but no data from a randomized clinical trial has been available. The present study aimed to evaluate the efficacy of bromhexine in intensive care unit (ICU) admission, mechanical ventilation, and mortality in patients with COVID-19. Methods: An open-label randomized clinical trial study was performed in Tabriz, North-West of Iran. They were randomized to either the treatment with the bromhexine group or the control group, in a 1:1 ratio with 39 patients in each arm. Standard therapy was used in both groups and those patients in the treatment group received oral bromhexine 8 mg three times a day additionally. The primary outcome was a decrease in the rate of ICU admissions, intubation/mechanical ventilation, and mortality. Results: A total of 78 patients with similar demographic and disease characteristics were enrolled. There was a significant reduction in ICU admissions (2 out of 39 vs. 11 out of 39, P = 0.006), intubation (1 out of 39 vs. 9 out of 39, P = 0.007) and death (0 vs. 5, P = 0.027) in the bromhexine treated group compared to the standard group. No patients were withdrawn from the study because of adverse effects. Conclusion: The early administration of oral bromhexine reduces the ICU transfer, intubation, and the mortality rate in patients with COVID-19. This affordable medication can easily be administered everywhere with a huge positive impact(s) on public health and the world economy. Altogether, the verification of our results on a larger scale and different medical centers is strongly recommended. Trial Registration: IRCT202003117046797N4; https://irct.ir/trial/46969.

    Search related documents:
    Co phrase search for related documents
    • accurate diagnosis and acute respiratory disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accurate diagnosis and admission high: 1, 2, 3
    • accurate diagnosis and admission rate: 1
    • accurate diagnosis and low intensity: 1
    • accurate diagnosis and lung damage: 1
    • accurate diagnosis and lung include: 1
    • accurate diagnosis and lung parenchyma: 1
    • accurate diagnosis and lung tissue: 1, 2, 3
    • accurate diagnosis and lymphocyte neutrophil: 1, 2, 3, 4
    • acute phase and admission baseline: 1
    • acute phase and admission high: 1, 2, 3
    • acute phase and admission rate: 1, 2
    • acute phase and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute phase and lung parenchyma: 1, 2, 3, 4
    • acute phase and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute phase and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • acute phase reactant and lymphocyte neutrophil: 1, 2
    • acute respiratory disease and admission baseline: 1, 2, 3, 4
    • acute respiratory disease and admission high: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14